News

WEST PALM BEACH, FL, USA — June 10, 2026 — Illumax, a Chinese innovative IVD manufacturer specializing in POCT chemiluminescence, multiplex immunoassay and flow cytometry solutions, showcased its cutting-edge multimodal diagnostic portfolio at CYTO 2026, the world’s premier conference for cytometry hosted by the International Society for Advancement of Cytometry (ISAC).

The X16 and X100 platforms have obtained NMPA registration in 2026 under a flexible “one certificate, multiple configurations” scheme, covering standalone and combined-method configurations. The X16 serves as a compact, agile model for mid-to-low throughput needs, while the X100 addresses high-volume laboratory workflows. Together they form Illumaxbio’s dual-product matrix to fulfill diverse clinical demands, from grassroots clinics to tertiary hospitals.

Illumax’s proprietary flow fluorometry technology drew strong interest from global cytometry specialists. Built on self-developed magnetic separation modules and encoded microspheres, the platform supports simultaneous multi-marker testing for cytokines, autoantibodies, allergens and immune function panels. It breaks the long-standing high-cost barrier of conventional flow cytometry systems dominated by Western vendors, bringing affordable, high-performance multiplex immune testing to emerging markets worldwide.

CYTO 2026 marked an important milestone for Illumax’s global cytometry roadmap. The company stated it will continue advancing the integration of flow cytometry, flow fluorometry and chemiluminescence, and roll out more clinically oriented reagent panels to empower standardized, accessible immune monitoring across the globe.